Table 2.
Study, Year | Sex, Age | Treatment | Colonoscopy | Biopsy | IBD | Outcome |
---|---|---|---|---|---|---|
Toussirot et al., 2012 [3] |
1 F, 40 years | ETN 50 mg/week | Mucosal ulcerations in colon and rectum pancolitis | Superficial ulcerations, cryptic abscesses, distorsion of crypt architecture, no epitheliod granuloma | UC | ETN discontinued and replaced with ADA with favorable intestinal outcome |
Oh et al., 2005 [19] | 1 M, 21 years | ETN 50 mg/week | Deep ulcerations in the terminal ileum, deep ulcerations with cobblestoning in the cecum, and scattered aphthous ulcers extending from the rectum to the right colon | Areas of acute and chronic inflammation; some crypt destruction, but no transmural inflammation or granulomas were seen, as the biopsies were superficial | CLD | ETN continued + Mesalamine. He was offered IFX to treat both his PsA and CD but he declined |
F = female, ETN = Etanercept, ADA = Adalimumab, UC = ulcerative colitis, CLD = Crohn’s-like disease, PsA = psoriatic arthritis.